Tivic Health Scales Up Entolimod Manufacturing with Velocity Bioworks Acquisition
I'm PortAI, I can summarize articles.
Tivic Health Systems Inc. has expanded its manufacturing capabilities by acquiring CDMO assets, now known as Velocity Bioworks. This acquisition allows Tivic to scale up production of its lead drug candidate, Entolimod, by 200 times. The company is preparing to manufacture under cGMP conditions, aiming to file a Biologics License Application with the FDA. This expansion is expected to improve operational efficiencies and accelerate commercialization.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments